Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa
Journal of the European Academy of Dermatology and Venereology · 2024-05 · 38 (5) · 904-909
DOI: 10.1111/jdv.19725 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 19.12.2023. Verfasst von P Aarts und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Adalimumab, Rifampin, Clindamycin. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Adalimumab monotherapy for hidradenitis suppurativa (HS) is often insufficient with a maximum clinical efficacy of 60% in Hidradenitis Suppurativa Clinical Response (HiSCR) and limited effect on draining tunnels. Data suggest that adalimumab therapy could be improved by concomitant antibiotics.
Objective
To compare the clinical effectiveness of adalimumab with clindamycin and rifampicin versus adalimumab monotherapy after 12 weeks.
Methods
This retrospective study included patients who started adalimumab with additional clindamycin and rifampicin and patients treated with adalimumab monotherapy, matched on sex and refined Hurley score. The primary outcome measure was the difference in change in the International Hidradenitis Suppurativa Severity Score System (IHS4) at 12 weeks.
Results
In total, 62 patients were included in the combination therapy group ( n = 31) and adalimumab monotherapy group ( n = 31), showing comparable IHS4 scores; 32.5 versus 29, p = 0.87 at baseline respectively. The combination therapy demonstrated greater clinical effectiveness expressed in median IHS4 improvement (−20 vs. −9, p < 0.001), IHS4‐55 (74% vs. 36%, p = 0.002), median draining tunnel reduction (−4 vs. −2, p < 0.001) and pain response (47% vs. 27%, p = 0.02).
Conclusion
Adalimumab initiated with clindamycin and rifampicin shows greater clinical effectiveness than adalimumab monotherapy. An important difference in effect was observed in the decrease of draining tunnels, addressing a serious limitation of adalimumab monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
ORCID-Profile: P Aarts, K R van Straalen
Zitieren
APA
Aarts, P., van Huijstee, J. C., van der Zee, H. H., van Straalen, K. R., & Prens, E. P. (2024). Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology, 38(5), 904-909. https://doi.org/10.1111/jdv.19725
Vancouver
Aarts P, van Huijstee JC, van der Zee HH, van Straalen KR, Prens EP. Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology. 2024;38(5):904-909. doi:10.1111/jdv.19725
BibTeX
@article{Aarts2024,
author = {Aarts, P and van Huijstee, J C and van der Zee, H H and van Straalen, K R and Prens, E P},
title = {Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
volume = {38},
number = {5},
pages = {904--909},
doi = {10.1111/jdv.19725}
}
EUVIMED